Myriad Genetics (MYGN) Operating Expenses (2009 - 2026)

Myriad Genetics has disclosed Operating Expenses across 18 years of filings, most recently posting $168.3 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 3.12% year-over-year to $168.3 million; the TTM figure through Mar 2026 stood at $968.9 million (up 37.14% YoY), while the FY2025 annual figure was $963.8 million, up 35.96% from the prior year.
• Operating Expenses advanced to $168.3 million in Q1 2026, from $152.5 million in the prior quarter.
• Over the last five years, Operating Expenses for MYGN reached as high as $481.0 million in Q2 2025 and fell as low as -$8.2 million in Q4 2023.
• The 5-year median for Operating Expenses is $183.6 million (2024), against an average of $190.1 million.
• Annual changes were most pronounced in 2023 — Operating Expenses tumbled 129.29% — and 2024, when it soared 2415.85%.
• A 5-year view of Operating Expenses shows it stood at $28.0 million in 2022, then tumbled by 129.29% to -$8.2 million in 2023, then soared by 2415.85% to $189.9 million in 2024, then decreased by 19.69% to $152.5 million in 2025, then climbed by 10.36% to $168.3 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $168.3 million, $152.5 million, and $167.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.